Historical case analysis, updated October 25, 2026
Quick answer: The March 28, 2025 Director Review decision in Motorola Solutions v. Stellar illustrates why the facts of parallel litigation matter to discretionary denial of an inter partes review. It does not establish that a patent is valid, guarantee a future denial, or prove that every startup portfolio has become more valuable.
What happened in Motorola v. Stellar?
In four identified IPR proceedings, the Director granted review, vacated the institution decisions and denied institution. The actual March 28, 2025 decision discusses investment in the parallel district-court proceeding and the scope of the petitioner’s Sotera stipulation. Read the decision and its procedural context rather than treating a headline as a general rule.
What is useful about the example?
The practical lesson is to examine duplication and case progress concretely. How much work has the court and the parties completed? What issues remain for each forum? Does a stipulation actually narrow the overlap? A promise not to raise particular grounds may leave other disputes for the court. Those are record-specific questions.
A denial of institution means that proceeding did not move to a PTAB trial. It is not a merits judgment that all challenged claims are valid or infringed. Other litigation, petitions and defenses can remain relevant. Institution policies and procedures can change; this article describes the dated decision, not a complete statement of every current institution rule.
What should a startup do with that information?
- Build a portfolio around the technical features and alternatives that matter commercially.
- Keep ownership, prosecution and disclosure records ready for diligence.
- Assess enforcement costs and invalidity risks rather than assuming a patent number creates leverage.
- When a dispute arises, ask counsel to compare the actual court record, petition grounds and current procedures.
Portfolio value still depends on claim coverage, validity, remaining term, ownership, evidence and the counterparty. A procedural development can affect risk without producing a measurable increase in the value of every patent.
Connect the portfolio to the business
For startup founders, a useful filing plan follows the product roadmap and financing milestones. For biotechnology companies and drug-development businesses, it also requires technical support for the claimed subject matter and coordination with development timelines. A transaction IP review should examine the actual assets and risks rather than rely on broad claims about an era of stronger patents.
Book a Free Consultation with Schell IP to discuss your portfolio and the business decision involved.
